Sunday 05 May 2024
Internal Reference Number: FOI_6575
Date Request Received: 03/05/2022 00:00:00
Date Request Replied To: 24/05/2022 00:00:00
This response was sent via: By Email
Request Summary: CLL and MCL
Request Category: Companies
| Question Number 1: How many patients has your trust treated in the past 3 months for the following conditions: • Chronic Lymphocytic Leukaemia (CLL) • Mantle Cell Lymphoma (MCL) • In case you do not treat either of the above conditions, please tell us which trust or hospital you refer patients to. | |
| Answer To Question 1: • Chronic Lymphocytic Leukaemia (CLL) 34 • Mantle Cell Lymphoma (MCL) 8 | |
| Question Number 2: How many Chronic Lymphocytic Leukaemia (CLL) patients have been treated in the past 3 months with the following: • BR (bendamustine + rituximab) • Calquence (acalabrutinib) • FCR (fludarabine + cyclophosphamide + rituximab) • Gazyva (obinutuzumab) + chlorambucil • Imbruvica (ibrutinib) • Venclexta (venetoclax) • Venclexta (venetoclax) + Gazyva (obinutuzumab) • Venclexta (venetoclax) + rituximab • Zydelig (idelalisib) + rituximab • Any other systemic anti-cancer therapy | |
| Answer To Question 2: • BR (bendamustine + rituximab) 0 • Calquence (acalabrutinib) 6 • FCR (fludarabine + cyclophosphamide + rituximab) 0 • Gazyva (obinutuzumab) + chlorambucil 0 • Imbruvica (ibrutinib) 11 • Venclexta (venetoclax) <5 • Venclexta (venetoclax) + Gazyva (obinutuzumab) 8 • Venclexta (venetoclax) + rituximab <5 • Zydelig (idelalisib) + rituximab 0 • Any other systemic anti-cancer therapy <5 | |
| Question Number 3: How many Mantle Cell Lymphoma (MCL) patients have been treated in the past 3 months with the following: • BR (bendamustine + rituximab) • Imbruvica (ibrutinib) • Imbruvica (ibrutinib) + rituximab • R-BAC (rituximab, bendamustine and cytarabine) • R-CHOP (rituximab + cyclophosphamide + doxorubicin + vincristine + prednisone) • Nordic Protocol (rituximab, cyclophosphamide, doxorubicin, vincristine, cytarabine & prednisolone) • Velcade (bortezomib) + chemotherapy • Any other systemic anti-cancer therapy • Stem cell transplant • Tecartus (CAR-T) - Autologous anti-CD19-transduced CD3+ cells | |
| Answer To Question 3: • BR (bendamustine + rituximab) 0 • Calquence (acalabrutinib) 6 • FCR (fludarabine + cyclophosphamide + rituximab) 0 • Gazyva (obinutuzumab) + chlorambucil 0 • Imbruvica (ibrutinib) 11 • Venclexta (venetoclax) 5 • Venclexta (venetoclax) + Gazyva (obinutuzumab) 8 • Venclexta (venetoclax) + rituximab <5 • Zydelig (idelalisib) + rituximab <5 • Any other systemic anti-cancer therapy <5 | |
| Question Number 4: Does your trust currently participate in any ongoing clinical trials for the treatment of Chronic Lymphocytic Leukaemia (CLL)? If so, can you please provide the name of each trial along with the number of patients taking part? | |
| Answer To Question 4: Admire recruited 7 patients Flair has recruited 10 so far | |
| Question Number 5: Does your trust currently participate in any ongoing clinical trials for the treatment of Mantle Cell Lymphoma (MCL)? If so, can you please provide the name of each trial along with the number of patients taking part? | |
| Answer To Question 5: Enrich recruited less than 5 patients | |
| To return to the list of all the FOI requests please click here |
Our staff at Salisbury District Hospital have long been well regarded for the quality of care and treatment they provide for our patients and for their innovation, commitment and professionalism. This has been recognised in a wide range of achievements and it is reflected in our award of NHS Foundation Trust status. This is afforded to hospitals that provide the highest standards of care.
